Breaking News, Trials & Filings

MedImmune Moves Asthma MAb to Phase II

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedImmune has initiated a Phase II clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of MEDI-563 a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody, according to the company. MEDI-563, which was generated using BioWa’s POTELLIGENT Technology...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters